Charlesson LLC

Description

Charlesson is a early stage drug development company focused on treating retinal diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD), among others. Charlesson was founded in 2003 by Dr. Jian-Xing Ma and Dr. Yan Feng. Dr. Ma, an expert in the field of diabetes research, realized the need for treatments for retinal diseases. The company has built a targeted approach towards its drug development starting with this underserved market. In addition to the markets, Charlesson strives to create solutions that are less invasive than the current standard of care. In addition to drug development, Charlesson has a world class contract research organization (CRO), which offers large and small companies alike many unique animal models and assays at affordable prices. Charlesson is completely private, and has been awarded a large number of state and federal grants through entities such as the National Institutes of Health (NIH), the Oklahoma Center for Advancement of Science and Technology (OCAST) and the Oklahoma Economic Development Generating Excellence (EDGE) Fund. To date Charlesson has raised over $10 million in funding and expects to be self sufficient through its first IND filing during the middle part of 2010. Charlesson’s lead candidate is CLT-003, which is a sustained release treatment for DME, for which no therapeutics are currently approved. Charlesson's headquarters are in Oklahoma City, where it employs over 20 people in the Presbyterian Health Foundation's Research Park, and The University of Oklahoma Health Sciences Center.

Companies nearby